IPEC, HIPEC, PIPAC, bidirektionale Chemotherapie und Immuntherapie bei Komplikationen der Peritonealkarzinose

[1]  C. Tempfer,et al.  Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy , 2016, World Journal of Surgical Oncology.

[2]  J. Raduà,et al.  Outcome prognostic factors in inoperable malignant bowel obstruction , 2016, Supportive Care in Cancer.

[3]  E. Cotte,et al.  Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy , 2016, Annals of Surgical Oncology.

[4]  D. Morris,et al.  Is the Combination of Distal Pancreatectomy and Cytoreductive Surgery With HIPEC Reasonable?: Results of an International Multicenter Study , 2016, Annals of surgery.

[5]  A. Lowy,et al.  Laparoscopy is Safe and Accurate to Evaluate Peritoneal Surface Metastasis Prior to Cytoreductive Surgery , 2016, Annals of Surgical Oncology.

[6]  H. Shibahara,et al.  Feasibility and efficacy of intraperitoneal docetaxel administration as salvage chemotherapy for malignant gynaecological ascites , 2015, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[7]  Ying Ding,et al.  A Comparative Analysis of Postoperative Pancreatic Fistulas After Surgery With and Without Hyperthermic Intraperitoneal Chemoperfusion , 2015, Annals of Surgical Oncology.

[8]  V. Servois,et al.  Recommendations for bowel obstruction with peritoneal carcinomatosis. , 2014, Journal of pain and symptom management.

[9]  W. Solass,et al.  Renal and Hepatic Toxicities After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) , 2013, Annals of Surgical Oncology.

[10]  P. Mariani,et al.  Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Sangha,et al.  Chemical Peritonitis After Intraperitoneal Sodium Thiosulfate , 2012, Peritoneal Dialysis International.

[12]  Y. Doki,et al.  Intraperitoneal docetaxel combined with S‐1 for advanced gastric cancer with peritoneal dissemination , 2012, Journal of surgical oncology.

[13]  M. Heiss,et al.  Catumaxomab treatment of peritoneal carcinomatosis from EpCAM-positive cancer: Identification of biomarkers with relevance for improved efficacy and survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Heiss,et al.  The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis. , 2010, Future oncology.

[15]  P. Murawa,et al.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial , 2010, International journal of cancer.

[16]  W. Hohenberger,et al.  Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis , 2009, Journal of surgical oncology.

[17]  J. Esquivel,et al.  Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination , 2008, Journal of surgical oncology.

[18]  R. Kimmig,et al.  Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study , 2007, Clinical Cancer Research.

[19]  M. Heiss,et al.  Immunotherapy of peritoneal carcinomatosis. , 2007, Cancer treatment and research.

[20]  J. Esquivel,et al.  Prospective Morbidity and Mortality Assessment of Cytoreductive Surgery Plus Perioperative Intraperitoneal Chemotherapy To Treat Peritoneal Dissemination of Appendiceal Mucinous Malignancy , 2006, Annals of Surgical Oncology.

[21]  M Vasei,et al.  Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers , 2006, British Journal of Cancer.

[22]  R. Kimmig,et al.  Immunotherapy of malignant ascites with trifunctional antibodies , 2005, International journal of cancer.

[23]  Alessandro Lugli,et al.  Frequent EpCam protein expression in human carcinomas. , 2004, Human pathology.

[24]  P. Ruf,et al.  Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. , 2001, Blood.

[25]  B. Wollenberg,et al.  The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells , 2000, British Journal of Cancer.

[26]  J. Shepherd,et al.  Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. The Systematic Review Steering Committee. , 1999, Gynecologic oncology.

[27]  K. Broadley,et al.  Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers , 1999 .

[28]  B. Wollenberg,et al.  Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. , 1999, Journal of immunology.

[29]  L. Hültner,et al.  Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models. , 1996, Blood.

[30]  S. Thierfelder,et al.  Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. , 1995, Journal of immunology.

[31]  H. A. Bakker,et al.  Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule , 1994, The Journal of cell biology.